AUM Biosciences appoints Dr. Zou Bin as its Chief Scientific Officer in preparation for clinical development milestones

Singapore, 4 July 2019 – AUM Biosciences, the leading oncology-focused Asian biotechnology company today announced the appointment of Dr. Zou Bin as its Chief Scientific Officer.

Prior to joining AUM Biosciences, Dr. Zou Bin was the CEO and Co-Founder of Shanghai Blueray Biopharma, Co. Ltd and was responsible for developing a strong pipeline of lymphoma/lung cancer drugs and increased the company’s value to more than 100 million RMB. Dr. Zou Bin has an extensive medicinal chemistry experience in global pharma (Novartis Institute for Tropical Diseases) and has developed multiple pre-clinical candidates among which is NITD609 Phase II clinical trials. Dr. Zou Bin is the co-inventor of a number of patents and more than twenty publications in high impact journals which includes Science and Nature.

Dr. Zou Bin has obtained his PhD and post-doctoral training in Synthetic Chemistry with Professor Dawei Ma (Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences) and with Professor K. C. Nicolaou (Institute of Chemical and Engineering Sciences, A*Star, Singapore).

“I am excited to work with the highly-experienced team in AUM Biosciences to drive Asia-focused therapeutic innovation in oncology.

We are establishing our pipeline by partnering with leading research institutes. AUM001, for example, originally developed by Singapore national platform Experimental Drug and Development Center (EDDC), is actively progressed by AUM in clinical trials”, said Dr. Zou Bin.

“I am looking forward to leading further pre-clinical evaluations for our current pipeline and providing strong evidence or hypothesis for potential different clinical designs. Additionally, I am looking forward to contributing AUM’s visionary goals ”, he added.

Commenting on the appointment, Mr Vishal Doshi, Chairman & CEO, AUM Biosciences said, “I am delighted to welcome Dr. Zou Bin on board as the Chief Scientific Officer. With Dr. Zou on board, we have a new leader who will drive the organization‘s R&D in making AUM a very science focused organization and realize our commitment for developing Asia-focused cancer therapies. I am confident that AUM will benefit from Dr Zou’s unique combination of scientific and commercial expertise in pharmaceutical industry and look forward to working with him.”

About AUM Biosciences:

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies for patients with high unmet medical needs. Dedicated to unlocking the value in innovation, we harness the power of precision medicine, and digital health to support patients, physicians and our partners. AUM focuses on early-stage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

Led by a highly-experienced management team with over 70 years of oncology drug development experience combined, AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs.

Headquartered in Singapore, AUM is strategically positioned to work with, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally.

For more information, please visit www.aumbiosciences.com or contact pr@aumbiosciences.com